Investors consortium completed the $700m investment in Sana Biotechnology, a developer of engineered cells intended to be used as medicine for patients. "Sana is dedicated to modulating genes in cells as well as replacing damaged cells in the body. The commitment from this group of long-term investors enables us to concentrate on making discoveries that overcome the most important challenges to making gene and cell therapies that improve the lives of a broad swath of patients. I am proud of our progress to date in turning our technologies into potential therapies for serious diseases such as cancer, central nervous system diseases, heart disease and various genetic disorders," Steve Harr, Sana President and CEO